Myhep All is a direct-acting antiviral (DAA) medication. DAAs are a group of medications that directly block the ability of the hepatitis C virus to make copies of itself. These medicines work by weakening the activity of proteins needed by hepatitis C.

One of the two drugs in Myhep All is Sofosbuvir, which is a nucleotide polymerase inhibitor, and the other is Velpatasvir, which is an NS5A (hepatitis C virus non-structural protein 5A) inhibitor. Sofosbuvir interferes with the reproduction of the genetic material of the hepatitis C virus. Velpatasvir works by interfering with a protein needed by the virus. Together these two medications greatly reduce and then stop the production of new copies of hepatitis C viruses.